# Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00669617** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 89 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol
- **DRUG:** Salmeterol/fluticasone (50/500 μg)
- **DRUG:** Salbutamol (200 µg)
- **DRUG:** Placebo to Indacaterol
- **DRUG:** Placebo to Salmeterol/fluticasone
- **DRUG:** Placebo to salbutamol

## Key facts

- **NCT ID:** NCT00669617
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2011-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669617, "Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00669617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*